HCC is a major health problem worldwide and, although we have made progress in preventing it, treatment of HCC is just getting started. TARGET-HCC collects real world data on HCC treatment at academic sites, in clinical practice, through the US and in Europe. TARGET-HCC is an important tool for tracking our progress towards complete control of HCC.
Adrian Di Bisceglie, MD
To date, significant research progress has been made in the field of Hepatocellular Carcinoma (HCC). However, the disease continues to be the most common type of primary liver cancer, further supporting the need for real-world data and insights to appropriately address gaps and advance the disease field.
TARGET-HCC is a 5-year longitudinal, observational study of the natural history and management of patients with HCC, within academic and community practices. The study was launched to collect real-world patient data to better understand the clinical characteristics, patterns, outcomes, and management of this disease in the real-world setting as well as assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
The HCC platform aggregates structured and unstructured data from medical records and patient-reported outcome measures and collects biospecimen samples. Partners can query the longitudinal dataset and analyses biospecimens linked to validated clinical data to support their drug development programs and RWE initiatives.